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ABSTRACT
Abstract: Objectives: The current assessment of
insulin resistance (IR) in epidemiology studies relies on
the blood measurement of C-peptide or insulin. A urine
C-peptide creatinine ratio (UCPCR) can be posted from
home unaided. It is validated against serum measures
of the insulin in people with diabetes. We tested
whether UCPCR could be a surrogate measure of IR by
examining the correlation of UCPCR with serum
insulin, C-peptide and HOMA2 (Homeostasis Model
Assessment 2)-IR in participants without diabetes and
with chronic kidney disease (CKD).
Design: Observational study.
Setting: Single-centre clinical research facility.
Participants: 37 healthy volunteers and 30 patients
with CKD (glomerular filtration rate 15–60) were
recruited.
Primary and secondary endpoints: Serum insulin,
C-peptide and glucose at fasting (0), 30, 60, 90 and
120 min were measured during an oral glucose
tolerance test (OGTT). Second-void fasting UCPCR and
120 min post-OGTT UCPCR were collected. HOMA2-IR
was calculated using fasting insulin and glucose. The
associations between UCPCR and serum measures
were assessed using Spearman’s correlations.
Results: In healthy volunteers, fasting second-void
UCPCR strongly correlated with serum insulin (rs=0.69,
p<0.0001), C-peptide (rs=0.73, p<0.0001) and HOMA2-
IR (rs=−0.69, p<0.0001). 120 min post-OGTT UCPCR
correlated strongly with C-peptide and insulin area under
the curve. In patients with CKD, UCPCR did not correlate
with serum C-peptide, insulin or HOMA2-IR.
Conclusions: In participants with normal renal function,
UCPCR may be a simple, practical method for the
assessment of IR in epidemiology studies.
BACKGROUND
Insulin resistance has been shown to be a sig-
nificant predictor for the development of dia-
betes and for cardiovascular risk.1 2
Understanding the epidemiology of insulin
resistance is important in the identification of
patients at risk of type 2 diabetes (T2D) and
vascular disease, and for the study of preven-
tion. The optimum individual method to
assess insulin physiology uses glucose disposal
rate during hyperinsulinaemic-euglycaemic
clamp studies,3 4 which require infusions of
insulin and glucose and cannot be used at a
population level. The minimal model analysis
of glucose and insulin levels during intraven-
ous or oral glucose loading allows assessment
without the use of intravenous insulin, but still
necessitates multiple blood samples.5 The
assessment of fasting insulin alone, or with
measures of glucose, have been used as a more
simple method to study insulin resistance6 and
have been validated against other more inva-
sive tests.7 One widely used approach that
allows for variation in the fasting glucose is the
Homeostasis Model Assessment (HOMA,
http://www.dtu.ox.ac.uk/homacalculator/
index.php)8 9 that models fasting serum
glucose, and insulin or C-peptide levels to cal-
culate the insulin resistance. HOMA requires
that a fasting blood sample is taken and the
sample is relatively rapidly processed within
24 h.10 This means an appointment with
Strengths and limitations of this study
▪ This study uses the clinical research facility
setting and samples sent from home to demon-
strate that urine C-peptide creatinine ratio
(UCPCR) can be used in healthy volunteers.
▪ UCPCR is compared with other epidemiological
measures of insulin resistance such as fasting
insulin and Homeostasis Model Assessment.
▪ UCPCR is not valid in people with chronic kidney
disease stages 3–5.
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healthcare or research staff is still required and this is not
always readily available for some large epidemiological
studies.
An alternative method to blood sampling, which
allows samples to be provided without outside assistance,
is to measure urinary C-peptide. C-peptide is secreted in
equimolar amounts to insulin, but unlike insulin, it is fil-
tered by the kidney with 5% excreted unchanged in the
urine, making urinary measures possible.11 We have
recently demonstrated that C-peptide is measureable,
reproducible and stable in urine for up to 72 h in boric
acid preservative (allowing postage from primary care or
from home).12 Measuring C-peptide as a ratio against
creatinine allows the use of a single-spot urine sample by
accounting for dilution in the same way as protein cre-
atinine ratio. In patients with T1D and T2D, 2 h urine
C-peptide creatinine ratio (UCPCR) is highly correlated
with 90 min serum C-peptide in the standard Mixed
Meal Tolerance Test.13 14 We have also shown that in
patients with T2D and mild chronic kidney disease
(CKD), the correlation between serum C-peptide and
urine is maintained.15 As fasting serum insulin or
C-peptide alone is a helpful marker of insulin resistance
in people without diabetes, it may be that UCPCR could
also be used in this manner.
If UCPCR can be used in people without diabetes this
practical method could allow a large scale, population-
based assessment of insulin resistance without needing a
blood sample to be taken. We aimed to test whether
UCPCR could be used as a surrogate measure of insulin
resistance in epidemiological studies by examining the
correlation of UCPCR with fasting serum insulin,
C-peptide and HOMA2-IR (HOMA2-insulin resistance)
in participants without diabetes. As a secondary
outcome we tested whether stimulated UCPCR could be
used as a marker of insulin secretion during an oral
glucose tolerance test (OGTT). We also wanted to see if
the correlations were maintained in participants with
chronic kidney disease.
METHODS
Study participants
Two groups were recruited from December 2009 to May 2010:
Thirty-seven healthy controls (22 females) with
normal renal function estimated glomerular filtration
(eGFR>60 mL min−1/m−2) and normal glucose toler-
ance16 17 were recruited from research volunteer data-
bases in Devon.
Thirty patients (8 females) with normal glucose toler-
ance and a clinical diagnosis of CKD stage 3 or greater
(Modification of Diet in Renal Disease (MDRD)
eGFR<60 mL min−1/m−2) (http://www.renal.org/
CKDguide/full/UKCKDfull.pdf) were recruited from
general nephrology clinics at the Royal Devon and
Exeter Hospital. Patients on renal replacement therapy
(either dialysis or transplant) were excluded from the
study.
Clinical sampling
Participants fasted from midnight prior to their visit and
emptied their bladder on waking (this first-void urine
was not collected). Demographic data, medical and
drug history were recorded. Baseline fasting blood
samples were collected for routine analysis of glucose,
glycated haemoglobin and renal function. A second
urine sample (second-void fasting) was collected imme-
diately prior to OGTT for measurement of UCPCR
(UCPCR0).6
In a standard OGTT (75 g glucose), blood samples
were collected at 30, 60, 90 and 120 min. A further
urine sample was collected for UCPCR analysis at
120 min (UCPCR120). Blood samples were immediately
centrifuged and separated. Serum and urine samples
were initially stored at −20°C then transferred and
stored at −80°C within 1 week. Serum samples were sub-
sequently analysed for insulin, C-peptide and glucose.
Urine samples were analysed for C-peptide and creatin-
ine and UCPCR was calculated.
Biochemical analysis
Urine and serum C-peptide analysis were performed by
electrochemiluminescence immunoassay (Roche
Diagnostics E170 C-peptide assay, Mannheim, Germany).
All urine samples were prediluted 1:10 with equine serum
albumin (diluent multianalyte, Roche Diagnostics). The
serum insulin analysis was performed by electrochemilu-
minescence immunoassay (Roche Diagnostics E170
insulin assay). Glucose and creatinine were analysed on
the Roche P800 modular platforms. All analysis was per-
formed in the Department of Chemical Pathology, Royal
Devon and Exeter Hospital. eGFR was calculated using
four-variable MDRD formula.18
Data analysis
Serial serum C-peptide, insulin and glucose measure-
ments were used to calculate area under the curve
(AUC) for each parameter. Insulin resistance
(HOMA2-IR) was derived from fasting glucose and
insulin (http://www.dtu.ox.ac.uk/homacalculator/
index.php). The associations between second-void
UCPCR0 and stimulated UCPCR120 with serum
C-peptide, insulin and HOMA2-IR were assessed using
Spearman’s correlations. The analyses were performed
separately for the group with CKD and the group
without CKD. The data for UCPCR were non-normally
distributed so a non-parametric statistical testing was
used for analysis.
RESULTS
A summary of the characteristics of the study group is
shown in table 1. Three participants with CKD had
serum C-peptide samples that were not analysed due to
sampling problems; their results have been included in
analyses excluding those involving C-peptide values.
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In participants without renal disease fasting second-
void UCPCR0 strongly correlated with serum insulin
(rs=0.69, p<0.0001), C-peptide (rs=0.73, p<0.0001) and
HOMA2-IR (rs=−0.69, p<0.0001). Age and body mass
index (BMI) also correlated with HOMA2-IR (rs=0.50
and 0.52 respectively, p<0.0001 for both). Scatter plots
with Spearman’s correlations and regression lines are
shown in figure 1.
After OGTT, UCPCR120 values were higher than
UCPCR0 (3.8 vs 1.0 nmol/mmol, p<0.0001; table 2).
UCPCR120 correlated with serum insulin (rs=0.78,
p<0.0001) and C-peptide AUC (rs=0.8, p<0.0001). Scatter
plots with Spearman’s correlations and regression lines
are shown in figure 2.
In patients with CKD, median fasting (1.2 vs 0.7 nmol/L
p<0.0001) and stimulated (457 vs 294 nmol/L, p<0.0001)
serum C-peptide measures were higher than the partici-
pants without CKD, but serum insulin levels were not dif-
ferent (7685 vs 6180, p=0.4). Despite the higher level of
serum C-peptide, UCPCR0 was not different between the
two groups (1.0 vs 0.8, p=0.8) and UCPCR120 was lower in
the CKD group (3.8 vs 2.7, p=0.02). This is consistent with
a reduced renal clearance of C-peptide.
In contrast to healthy controls, there was no correlation
between UCPCR0 and fasting serum C-peptide (rs 0.17,
p=0.4), insulin (rs −0.17, p=0.4) or HOMA-IR (rs −0.16,
p=0.4) and no correlation between UCPCR120 and
C-peptide (rs=−0.09, p=1) or insulin AUC during the
OGTT (rs=0.26, p=0.2; figure 3).
DISCUSSION
Our study suggests that a fasting second-void morning
UCPCR could be used as a marker of insulin resistance
in participants without diabetes, as long as they are
known not to have chronic renal disease. The fact that
this test can be performed at home without the assist-
ance of healthcare or research staff offers the opportun-
ity to perform a simple assessment of insulin resistance
in large scale epidemiological studies.
UCPCR is not a replacement for established measures
of insulin resistance, but is an alternative measure of
fasting insulin. Numerous population-based studies have
used HOMA to estimate insulin resistance.9 Similarly,
there are many studies using euglycaemic clamps and
alternative methods such as minimal model analysis to
Table 1 Cohort characteristics.
Normal renal function group CKD group
Total participants 37 30
Female 22 8
Age (years) 50 (29–67) 65 (52–71)
BMI (kg/m2) 27.0 (23.5–33.0) 26.4 (24.1–28.6)
HbA1c (%) 5.7 (5.4–6.0) 5.9 (5.6–6.1)
Fasting blood glucose (mmol/L) 4.8 (4.5–5.1) 5.0 (4.5–5.3)
Creatinine (mmol/L) 77 (66–84) 195 (134–231)
MDRD eGFR (mL/min/1.73 m2) 88 (76–101) 32 (26–46)
Data are presented as median (IQR).
BMI, body mass index; CKD, chronic kidney disease; eGFR, estimated glomerular filtration; HbA1c, glycated haemoglobin;
MDRD, Modification of Diet in Renal Disease.
Figure 1 Scatter plots showing fasting second-void urine C-peptide creatinine ratio (UCPCR0) was strongly correlated with
fasting serum insulin (A) and Homeostasis Model Assessment2-insulin resistance (B) in 37 people with normal renal function.
Regression line Spearman’s rs correlations are shown. *p<0.0001. Stimulated UCPCR values were correlated with stimulated
values of serum insulin and C-peptide, in people without chronic kidney disease.
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study individual patients or small groups of patients.
UCPCR cannot be used as a direct substitute for these as
it only measures C-peptide, and although it shows a
strong correlation with HOMA2-IR, we have not vali-
dated it against the euglycaemic-hyperglycaemic clamp.
The similarity of the scatter plots for UCPCR0 against
HOMA2-IR and UCPCR0 against fasting insulin demon-
strates the large effect that fasting insulin values have on
HOMA-IR when participants do not have abnormal
fasting glucose. If the fasting glucose levels are elevated,
UCPCR will not correlate so well with HOMA-IR as ele-
vated glucose will start to have an effect on the calcula-
tion. This suggests that UCPCR may only be useful as a
marker of insulin resistance in populations who have
normal glucose tolerance. There was a correlation
between HOMA2-IR, age and BMI in our study, but the
variance explained by these simple measures was less
than UCPCR0 (r2=0.27 for BMI vs r2=0.48 for UCPCR0),
suggesting its additional benefit over these measures.
UCPCR is a non-invasive test and does not need proxim-
ity to a laboratory for immediate sample analysis. Rather
than replacing more complex measures of assessment of
insulin secretion or resistance, UCPCR is an alternative
where serum insulin or C-peptide analysis is impractical,
or the non-invasive nature of a urine test is preferred.
We collected second-void fasting urine samples
because we have shown this to be less variable than
first-void urine in people without diabetes.12 This is
because C-peptide secretion in response to the previ-
ous evening’s meal will accumulate in an overnight
urine sample. A second-void sample adds an extra
methodological step which may make sampling more
difficult in large studies. It would be interesting to see if
first-void urine correlated well with serum insulin and C-
peptide and there may be existing studies that have
serum and fasting first-void urine samples available to
easily test this.
A key finding of this study is that UCPCR0 and
UCPCR120 were not correlated with serum C-peptide or
insulin in participants with CKD. When comparing the
CKD group with the control participants, serum
C-peptide AUC was elevated in participants with CKD
whereas UCPCR120 was lower. This is explained by the
reduced renal clearance of C-peptide in CKD,11 leading
to higher C-peptide AUC values and lower UCPCR120
values. This impaired clearance may then explain the
lack of correlation in participants with CKD. The
number of patients in this study was too small to
compare the patients with different levels of GFR,
underlying causes of CKD and the presence of
Table 2 Median (IQR) serum insulin, C-peptide, UCPCR and HOMA-IR
Normal renal function group (n=38) CKD group (n=30)
Fasting C-peptide (nmol/L) 0.7 (0.5–1.0) 1.2 (0.8–1.6)
Fasting insulin (pmol/L) 8.1 (5.0–13.1) 8.8 (6.4–12.0)
C-peptide area under curve (nmol/L) 294 (207–405) 457 (371–550)
Insulin area under curve (pmol/L) 6180 (3641–11 994) 7685 (5050–9597)
UCPCR0 (nmol/mmol) 1.0 (0.6–1.4) 0.914 (0.5–1.5)
UCPCR120 (nmol/mmol) 3.8 (2.3–7.0) 2.8 (0.9–4.0)
HOMA2-IR 1.2 (0.8–1.9) 1.3 (0.9–1.7)
Fasting second-void UCPCR strongly correlated with serum insulin, C-peptide and HOMA2-IR in people without chronic kidney disease.
CKD, chronic kidney disease; HOMA2-IR, Homeostasis Model Assessment2-insulin resistance; UCPCR, urine C-peptide creatinine ratio.
Figure 2 Scatter plots showing 120 min post oral glucose tolerance test, urine C-peptide creatinine ratio (UCPCR120) was
strongly correlated to serum C-peptide (A) and insulin (B) area under the curve in 37 people with normal renal function.
Regression line Spearman’s rs correlations are shown. *p<0.0001.
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proteinuria. Further work will be needed to fully under-
stand the clearance of C-peptide in people with CKD.
These data suggest that UCPCR should not be used in
people without diabetes who have CKD. In our previ-
ously published study on patients with T2D, mild CKD
(in 23 participants) did not alter the association
between UCPCR and serum C-peptide.15 It is possible
that the presence of diabetes, more severe CKD
(median eGFR 33 (27–46) vs 51 (44–58) in Bowman’s
study) or relatively small numbers in both studies may
explain the difference between these two sets of results.
Our results suggest that further work may be needed to
assess the utility of UCPCR in participants with diabetes
and renal impairment.
This study is important because of the simplicity and
practicality of a UCPCR test rather than an ability to
more accurately describe insulin physiology in individual
participants. The current measures of insulin secretion
and sensitivity rely on serum assays of C-peptide and
insulin which require an access to centrifugation and
freezing within 24 h. This limits studies to centres with
these facilities and staff to use them. UCPCR could be
particularly useful in the developing world where the
diagnosis of diabetes is rising fastest and reduced facility
and staffing costs associated with a posted urine sample
may make large studies easier to do. Given the results
with CKD and the effect of elevated glucose levels on
HOMA-calculated insulin resistance, UCPCR may be
most useful in young-aged or middle-aged populations
where the background prevalence of CKD and diabetes
is low.
In conclusion, UCPCR0 and UCPCR120 correlate with
serum levels of insulin and C-peptide, and also with
HOMA2-calculated insulin resistance in patients without
diabetes. The practical aspects of performing UCPCR
testing make it a potentially useful method for the
assessment of insulin production and resistance in large
epidemiology studies. Patients with CKD should be
excluded from these studies.
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